Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Ratio (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Equity Ratio for 10 consecutive years, with 0.29 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 422.83% to 0.29 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.29, a 422.83% increase, with the full-year FY2025 number at 0.29, up 422.83% from a year prior.
  • Equity Ratio was 0.29 for Q4 2025 at Rhythm Pharmaceuticals, down from 0.29 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.91 in Q3 2021 to a low of 0.03 in Q2 2025.
  • A 5-year average of 0.49 and a median of 0.57 in 2023 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 851.8% in 2025; the steepest drop was 131.01% in 2025.
  • Rhythm Pharmaceuticals' Equity Ratio stood at 0.86 in 2021, then fell by 19.88% to 0.69 in 2022, then decreased by 26.16% to 0.51 in 2023, then plummeted by 89.14% to 0.06 in 2024, then soared by 422.83% to 0.29 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Equity Ratio are 0.29 (Q4 2025), 0.29 (Q3 2025), and 0.03 (Q2 2025).